Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 1/20 | 0.68 |
| ▸ | CDK9 | P50750 | 1/20 | 0.68 |
| ▸ | GPR6 | P46095 | 15/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | SRPK2 | P78362 | 1/20 | 0.42 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.42 |
| ▸ | SRPK3 | Q9UPE1 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23196454 | 0.90 | SRPK1 (0.53) | CDK4CDK9GPR6KDRSRPK2 | |
| SCHEMBL22700675 | 0.85 | CDK4 (0.77) | CDK4CDK9GPR6KDRSRPK2 | |
| SCHEMBL22700677 | 0.81 | CDK4 (1.00) | CDK4CDK9KDRSRPK2SRPK1 | |
| SCHEMBL14803325 | 0.81 | CDK4 (1.00) | CDK4CDK9KDRSRPK2SRPK1 | |
| SCHEMBL29407903 | 0.81 | CDK4 (1.00) | CDK4CDK9KDRSRPK2SRPK1 | |
| SCHEMBL29407904 | 0.81 | CDK4 (1.00) | CDK4CDK9KDRSRPK2SRPK1 | |
| SCHEMBL22700669 | 0.81 | CDK4 (0.44) | CDK4CDK9GPR6KDRSRPK2 | |
| SCHEMBL16697768 | 0.78 | CDK4 (0.75) | CDK4CDK9KDRSRPK2SRPK1 | |
| SCHEMBL22700672 | 0.74 | CDK4 (0.69) | CDK4CDK9KDRSRPK2SRPK1 | |
| SCHEMBL22700680 | 0.72 | SRPK1 (0.74) | CDK4CDK9KDRSRPK2SRPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210100781-A1 | TUMOR SUPPRESSION | KYOTO UNIVERSITY (JP) | 2021-04-08 | — | — | US | disclosed |
| WO-2020235672-A1 | PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE | 国立大学法人京都大学 (JP) | 2020-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210100781-A1 | TUMOR SUPPRESSION | TSG101, TP53, VHL | CDK4 2094/4885CDK9 3868/4885GPR6 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.